Cambridge Advisors’s Merck MRK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.01M | Buy |
7,852
+56
| +0.7% | +$6.55K | 0.17% | 84 |
|
|
2026
Q1 | $938K | Buy |
7,796
+12
| +0.2% | +$1.39K | 0.18% | 89 |
|
|
2025
Q4 | $819K | Sell |
7,784
-286
| -4% | -$26.8K | 0.16% | 94 |
|
|
2025
Q3 | $677K | Buy |
8,070
+14
| +0.2% | +$1.15K | 0.13% | 101 |
|
|
2025
Q2 | $638K | Sell |
8,056
-485
| -6% | -$38.6K | 0.13% | 106 |
|
|
2025
Q1 | $767K | Buy |
8,541
+12
| +0.1% | +$1.12K | 0.17% | 90 |
|
|
2024
Q4 | $848K | Sell |
8,529
-2,990
| -26% | -$308K | 0.19% | 82 |
|
|
2024
Q3 | $1.31M | Sell |
11,519
-51
| -0.4% | -$6.06K | 0.29% | 58 |
|
|
2024
Q2 | $1.43M | Buy |
11,570
+154
| +1% | +$19.8K | 0.33% | 48 |
|
|
2024
Q1 | $1.51M | Buy |
11,416
+524
| +5% | +$64.6K | 0.36% | 48 |
|
|
2023
Q4 | $1.19M | Buy |
10,892
+10
| +0.1% | +$1.04K | 0.3% | 56 |
|
|
2023
Q3 | $1.12M | Sell |
10,882
-891
| -8% | -$96K | 0.3% | 56 |
|
|
2023
Q2 | $1.36M | Sell |
11,773
-2,216
| -16% | -$252K | 0.35% | 43 |
|
|
2023
Q1 | $1.49M | Buy |
13,989
+150
| +1% | +$16.2K | 0.38% | 40 |
|
|
2022
Q4 | $1.54M | Sell |
13,839
-5
| -0% | -$511 | 0.41% | 38 |
|
|
2022
Q3 | $1.19M | Sell |
13,844
-390
| -3% | -$34.8K | 0.34% | 48 |
|
|
2022
Q2 | $1.3M | Sell |
14,234
-550
| -4% | -$48.8K | 0.35% | 47 |
|
|
2022
Q1 | $1.21M | Buy |
14,784
+11
| +0.1% | +$867 | 0.29% | 61 |
|
|
2021
Q4 | $1.13M | Buy |
14,773
+283
| +2% | +$22.5K | 0.26% | 66 |
|
|
2021
Q3 | $1.09M | Buy |
14,490
+11
| +0.1% | +$837 | 0.27% | 66 |
|
|
2021
Q2 | $1.13M | Sell |
14,479
-778
| -5% | -$57.9K | 0.27% | 67 |
|
|
2021
Q1 | $1.12M | Buy |
15,257
+11
| +0.1% | +$811 | 0.29% | 63 |
|
|
2020
Q4 | $1.19M | Buy |
15,246
+10
| +0.1% | +$765 | 0.32% | 57 |
|
|
2020
Q3 | $1.21M | Buy |
15,236
+11
| +0.1% | +$862 | 0.36% | 49 |
|
|
2020
Q2 | $1.12M | Buy |
15,225
+10
| +0.1% | +$753 | 0.35% | 49 |
|
|
2020
Q1 | $1.12M | Buy |
15,215
+61
| +0.4% | +$4.79K | 0.41% | 40 |
|
|
2019
Q4 | $1.31M | Sell |
15,154
-240
| -2% | -$19.7K | 0.4% | 45 |
|
|
2019
Q3 | $1.24M | Sell |
15,394
-306
| -2% | -$24.5K | 0.41% | 39 |
|
|
2019
Q2 | $1.26M | Sell |
15,700
-2,453
| -14% | -$188K | 0.41% | 40 |
|
|
2019
Q1 | $1.44M | Sell |
18,153
-1,278
| -7% | -$95.6K | 0.49% | 38 |
|
|
2018
Q4 | $1.42M | Sell |
19,431
-516
| -3% | -$36.4K | 0.53% | 37 |
|
|
2018
Q3 | $1.35M | Buy |
19,947
+11
| +0.1% | +$701 | 0.46% | 42 |
|
|
2018
Q2 | $1.16M | Buy |
19,936
+989
| +5% | +$55.8K | 0.41% | 49 |
|
|
2018
Q1 | $985K | Buy |
18,947
+440
| +2% | +$23.8K | 0.35% | 56 |
|
|
2017
Q4 | $994K | Sell |
18,507
-24
| -0.1% | -$1.33K | 0.36% | 54 |
|
|
2017
Q3 | $1.13M | Sell |
18,531
-524
| -3% | -$31.8K | 0.44% | 43 |
|
|
2017
Q2 | $1.17M | Sell |
19,055
-1,048
| -5% | -$63.8K | 0.47% | 40 |
|
|
2017
Q1 | $1.22M | Hold |
20,103
| – | – | 0.5% | 40 |
|
|
2016
Q4 | $1.13M | Hold |
20,103
| – | – | 0.5% | 44 |
|
|
2016
Q3 | $1.2M | Hold |
20,103
| – | – | 0.53% | 43 |
|
|
2016
Q2 | $1.1M | Hold |
20,103
| – | – | 0.5% | 43 |
|
|
2016
Q1 | $1.01M | Hold |
20,103
| – | – | 0.47% | 47 |
|
|
2015
Q4 | $1.01M | Sell |
20,103
-78
| -0.4% | -$3.93K | 0.57% | 44 |
|
|
2015
Q3 | $951K | Buy |
20,181
+628
| +3% | +$33.4K | 0.56% | 48 |
|
|
2015
Q2 | $1.06M | Sell |
19,553
-28,217
| -59% | -$1.58M | 0.6% | 42 |
|
|
2015
Q1 | $1.85M | Buy |
47,770
+28,217
| +144% | +$1.6M | 1.08% | 26 |
|
|
2014
Q4 | $1.06M | Buy |
+19,553
| New | +$1.09M | 0.65% | 42 |
|
Other funds holding MRK
ECSS
Cambridge Advisors's MRK Position: Q2 2026 in Review
Cambridge Advisors increased its Merck (MRK) stake by 0.72% in Q2 2026, buying an estimated $6.55K and bringing the position to 7,852 shares worth $1.01M. The position accounts for 0.17% of the portfolio, ranked #84.
Cambridge Advisors first reported a position in MRK in Q4 2014 and has held it in 47 quarters since. The position peaked at $1.85M in Q1 2015. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.
- Cambridge Advisors held 7,852 shares of Merck worth $1.01M as of Q2 2026.
- Cambridge Advisors bought 56 Merck shares in Q2 2026, an estimated $6.55K.
- Merck made up 0.17% of Cambridge Advisors's portfolio in Q2 2026, its #84 holding.
- Cambridge Advisors first reported a position in Merck in Q4 2014 and has held it in 47 quarters since.
- Cambridge Advisors's Merck position peaked at $1.85M in Q1 2015.
- 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.
Based on Cambridge Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.